Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition

In recent years, immune checkpoint inhibitors (ICIs) targeting CTLA-4 or PD1/PDL1 have achieved remarkable success in the treatment of bladder cancer (BLCA), but only a few patients have shown durable clinical benefits. The prognostic role of a mutant form of the tumor suppressor gene TP53 (TP53-MT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Qiong, Lin, Anqi, Cao, Manming, Xu, Abai, Luo, Peng, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480364/
https://www.ncbi.nlm.nih.gov/pubmed/33356494
http://dx.doi.org/10.1177/1073274820976665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480364/
https://www.ncbi.nlm.nih.gov/pubmed/33356494
http://dx.doi.org/10.1177/1073274820976665

Ejemplares similares